International Journal of Advance Research Publication and Reviews

International Journal of Advance Research Publication and Reviews
Peer-Reviewed | Multi-Disciplinary Journal

ISSN: 3049-0103 (O)

Impact Factor: 4.33

Advancement of Floating Drug Delivery System for the Treatment of Parkinson’s Disease

Author

Soumyaranjan Sahoo, Sritam Behera

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder requir-ing continuous dopaminergic stimulation. The primary pharmacological treatment, Levodopa (often combined with Carbidopa), suffers from a narrow absorption win-dow confined to the proximal small intestine. Conventional dosage forms lead to fluctuating plasma drug levels, resulting in ”on-off” motor fluctuations. To over-come these pharmacokinetic limitations, Gastroretentive Floating Drug Delivery Systems (FDDS) have emerged as a promising strategy. This paper reviews and investigates the advancement of FDDS in prolonging the gastric residence time (GRT) of anti-Parkinson’s drugs, thereby ensuring sustained release and improved bioavailability. The study presents a comprehensive framework, formulation param-eters, and analytical results demonstrating the efficacy of floating matrix systems using hydrophilic polymers like HPMC.

Keywords

Parkinson’s disease, Floating Drug Delivery System, Levodopa, Gastric Residence Time, Bioavailability, Buoyancy

Full Text:

Download Paper PDF

References

  1. Arora, S., Ali, J., Ahuja, A., Khar, R. K., & Baboota, S. (2005).Floating drug delivery systems: A review. AAPS PharmSciTech, 6(3), E372-E390.
  2. Bardonnet, P. L., Faivre, V., Pugh, W. J., Piffaretti, J. C., & Falson, F. (2006). Gastroretentivedosage forms: Overview and special case of Helicobacter  Journal of Controlled Release, 111(1-2), 1-18.
  3. Baumgartner, S., Kristl, J., Vreˇcer,, Vodopivec, P., & Zorko, B. (2000). Opti-misation of floating matrix tablets and evaluation of their gastric residence time. International Journal of Pharmaceutics, 195(1-2), 125-135.
  4. Chawla, G., Gupta, P., Koradia, V., & Bansal, A. K. (2003).Gastroretention: A means to address regional variability in intestinal drug absorption. Pharmaceutical Technology, 27(2), 50-68.
  5. Chen, Y. C., & Ho, H. O. (2004).Development and evaluation of a multiple-unit floating drug delivery system for  International Journal of Pharmaceutics, 276(1-2), 11-20.
  6. Garg, R., & Gupta, G. D. (2008).Progress in controlled gastroretentive delivery systems. Tropical Journal of Pharmaceutical Research, 7(3), 1055-1066.
  7. Goole, J., Vanderbist, F., & Amighi, K. (2008).Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. International Journal of Pharmaceutics, 334(1-2), 35-41.

 

  1. Hoffman,, Stepensky, D., Lavy, E., Eyal, S., Klausner, E., & Friedman, M. (2004). Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. International Journal of Pharmaceutics, 277(1-2), 141-153.
  2. Hwang, J., Park, H., & Park, K. (1998). Gastric retentive drug-delivery systems.

Critical Reviews in Therapeutic Drug Carrier Systems, 15(3), 243-284.

  1. Jain, K., Agrawal, G. P., & Jain, N. K. (2006). Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery. AAPS PharmSciTech, 7(4), 54-62.
  2. Klausner, E. A., Lavy, E., Friedman, M., & Hoffman, A. (2003).Expandable gastroretentive dosage forms. Journal of Controlled Release, 90(2), 143-162.
  3. Li,, Lin, S., Daggy, B. P., Mirchandani, H. L., & Chien, Y. W. (2003). Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Development and Industrial Pharmacy, 29(2), 137-147.
  4. Nayak, A. K., Maji, R., & Das, B. (2010).Gastroretentive drug delivery systems: A review. Asian Journal of Pharmaceutical and Clinical Research, 3(1), 2-10.
  5. Pahwa,, Saini, N., Kumar, V., & Kohli, K. (2012). Chitosan-based gastrore-tentive floating drug delivery technology: An overview. Expert Opinion on Drug Delivery, 9(5), 525-539.
  6. Pawar, V. K., Kansal, S., Garg, G., Awasthi, R., Singodia, D., & Kulkarni, G. T. (2011).Gastroretentive dosage forms: A review with special emphasis on floating drug delivery  Drug Delivery, 18(2), 97-110.
  7. Rouge, N., Buri, P., & Doelker, E. (1996).Drug absorption sites in the gastroin-testinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 136(1-2), 117-139.
  8. Sahoo, S., & Behera, S. (2022).Innovations in Hydrophilic Matrix Systems for Targeted GI Delivery. Journal of Applied Pharmaceutics, 12(4), 112-120.
  9. Singh, N., & Kim, K. H. (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 63(3), 235-259.
  10. Streubel, A., Siepmann, J., & Bodmeier, R. (2006).Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 3(2), 217-233.
  11. Timmermans,, & Moes, A. J. (1990). How well do floating dosage forms float?

International Journal of Pharmaceutics, 62(2-3), 207-216.

Top